Vetter Pharma

Vetter Pharma, headquartered in Germany and operating in the Surgical and Medical Instrument Manufacturing industry, has established clear climate commitments and is actively reporting on its carbon emissions.

For the reporting year 2025, Vetter Pharma reported a total of approximately 27.5 million kg CO2e across Scope 1 and Scope 3 emissions. Scope 1 emissions were approximately 1.7 million kg CO2e, primarily from stationary combustion. Scope 3 emissions accounted for the majority, totalling approximately 25.7 million kg CO2e, with purchased goods and services being the largest contributor. Scope 2 emissions were reported as zero for this year.

In previous years, total reported emissions have varied:

• 2024: Approximately 20.7 million kg CO2e (Scope 1: approximately 17.0 million kg CO2e, Scope 3: approximately 3.7 million kg CO2e). Scope 2 emissions were zero.
• 2023: Approximately 21.5 million kg CO2e (Scope 1: approximately 17.9 million kg CO2e, Scope 3: approximately 3.6 million kg CO2e). Scope 2 emissions were not reported.
• 2022: Approximately 20.9 million kg CO2e (Scope 1: approximately 18.0 million kg CO2e, Scope 3: approximately 2.9 million kg CO2e). Scope 2 emissions were not reported.
• 2021: Approximately 19.7 million kg CO2e (Scope 1: approximately 19.7 million kg CO2e, Scope 2: zero, Scope 3: approximately 0.2 million kg CO2e).

Vetter Pharma has set ambitious reduction targets:

• A long-term goal to achieve net-zero emissions by 2050.
• As a near-term goal, currently being validated by the Science Based Targets initiative (SBTi), Vetter Pharma aims to reduce its combined Scope 1 and 2 greenhouse gas emissions by 58.8% by 2034, compared to a 2021 baseline. This commitment is aligned with keeping global warming to 1.5°C.
• Additionally, the company commits that 80% of its suppliers by spend, covering purchased goods and services, capital goods, and upstream transportation and distribution, will have science-based targets by 2029.